Format
Sort by
Items per page

Send to

Choose Destination

Best matches for brca1 protein AND brca2 protein AND malignant neoplasm of breast AND mutation:

Search results

Items: 1 to 20 of 2093

1.

A Novel Germline Mutation in <i>BRCA1</i> Causes Exon 20 Skipping in a Korean Family with a History of Breast Cancer.

Yoon KA, Kong SY, Lee EJ, Cho JN, Chang S, Lee ES.

J Breast Cancer. 2017 Sep;20(3):310-313. doi: 10.4048/jbc.2017.20.3.310. Epub 2017 Sep 22.

2.

Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy.

Saule C, Mouret-Fourme E, Briaux A, Becette V, Rouzier R, Houdayer C, Stoppa-Lyonnet D.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx159.

PMID:
28954295
3.

Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.

Lee YC, Milne RL, Lheureux S, Friedlander M, McLachlan SA, Martin KL, Bernardini MQ, Smith C, Picken S, Nesci S, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).

Eur J Cancer. 2017 Oct;84:114-120. doi: 10.1016/j.ejca.2017.07.004. Epub 2017 Aug 10.

PMID:
28802188
4.

The risk of breast cancer due to PALB2 gene mutations.

Wesoła M, Jeleń M.

Adv Clin Exp Med. 2017 Mar-Apr;26(2):339-342. doi: 10.17219/acem/59147. Review. No abstract available.

5.

Fertility and pregnancy issues in BRCA-mutated breast cancer patients.

Lambertini M, Goldrat O, Toss A, Azim HA Jr, Peccatori FA, Ignatiadis M, Del Mastro L, Demeestere I.

Cancer Treat Rev. 2017 Sep;59:61-70. doi: 10.1016/j.ctrv.2017.07.001. Epub 2017 Jul 14. Review.

PMID:
28750297
6.

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.

Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler RK.

JAMA Oncol. 2017 Oct 1;3(10):1378-1385. doi: 10.1001/jamaoncol.2017.1007.

PMID:
28715532
7.

[Breast Cancer in Young Women - Correlation of Clinical Histomorphological, and Molecular-genetic Features of Breast Carcinoma in Women Younger than 35 Years of Age].

Metelková A, Skálová A, Fínek J.

Klin Onkol. Summer 2017;30(3):202-209. doi: 10.14735/amko2017202. Czech.

PMID:
28612617
8.

Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.

Stafford JL, Dyson G, Levin NK, Chaudhry S, Rosati R, Kalpage H, Wernette C, Petrucelli N, Simon MS, Tainsky MA.

PLoS One. 2017 Jun 7;12(6):e0178450. doi: 10.1371/journal.pone.0178450. eCollection 2017.

9.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P.

N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4.

PMID:
28578601
10.

Aldehydes Pose a Threat to BRCA2 Mutation Carriers.

Parmar K, D'Andrea AD.

Cell. 2017 Jun 1;169(6):979-981. doi: 10.1016/j.cell.2017.05.021.

PMID:
28575676
11.

Co-Occurrence of COMT and BRCA1/2 Variants in a Population.

Movassagh M, Mudvari P, Horvath A.

N Engl J Med. 2017 May 25;376(21):2090-2091. doi: 10.1056/NEJMc1701592. No abstract available.

12.

Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.

Espenschied CR, LaDuca H, Li S, McFarland R, Gau CL, Hampel H.

J Clin Oncol. 2017 Aug 1;35(22):2568-2575. doi: 10.1200/JCO.2016.71.9260. Epub 2017 May 17.

PMID:
28514183
13.

Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53.

Lolas Hamameh S, Renbaum P, Kamal L, Dweik D, Salahat M, Jaraysa T, Abu Rayyan A, Casadei S, Mandell JB, Gulsuner S, Lee MK, Walsh T, King MC, Levy-Lahad E, Kanaan M.

Int J Cancer. 2017 Aug 15;141(4):750-756. doi: 10.1002/ijc.30771. Epub 2017 May 19.

PMID:
28486781
14.

Antimüllerian hormone levels are lower in BRCA2 mutation carriers.

Johnson L, Sammel MD, Domchek S, Schanne A, Prewitt M, Gracia C.

Fertil Steril. 2017 May;107(5):1256-1265.e6. doi: 10.1016/j.fertnstert.2017.03.018.

PMID:
28476184
15.

Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.

Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, Ruscito I, Farooqi AA, Papadia A, Mueller MD, Ferretti E, Benedetti Panici P.

Tumour Biol. 2017 May;39(5):1010428317695525. doi: 10.1177/1010428317695525. Review.

PMID:
28459207
16.

Therapeutic targeting and patient selection for cancers with homologous recombination defects.

Talens F, Jalving M, Gietema JA, Van Vugt MA.

Expert Opin Drug Discov. 2017 Jun;12(6):565-581. doi: 10.1080/17460441.2017.1322061. Epub 2017 May 2. Review.

PMID:
28425306
17.

The Role of Genetic Testing in Patients With Breast Cancer: A Review.

Valencia OM, Samuel SE, Viscusi RK, Riall TS, Neumayer LA, Aziz H.

JAMA Surg. 2017 Jun 1;152(6):589-594. doi: 10.1001/jamasurg.2017.0552. Review.

PMID:
28423155
18.

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.

Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, Hallberg E, Moore R, Thomas A, Lilyquist J, Feng B, McFarland R, Pesaran T, Huether R, LaDuca H, Chao EC, Goldgar DE, Dolinsky JS.

JAMA Oncol. 2017 Sep 1;3(9):1190-1196. doi: 10.1001/jamaoncol.2017.0424.

PMID:
28418444
19.

Online self-test identifies women at high familial breast cancer risk in population-based breast cancer screening without inducing anxiety or distress.

van Erkelens A, Sie AS, Manders P, Visser A, Duijm LE, Mann RM, Ten Voorde M, Kroeze H, Prins JB, Hoogerbrugge N.

Eur J Cancer. 2017 Jun;78:45-52. doi: 10.1016/j.ejca.2017.03.014. Epub 2017 Apr 14.

PMID:
28412588
20.

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.

Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, Rahman N.

Value Health. 2017 Apr;20(4):567-576. doi: 10.1016/j.jval.2017.01.004. Epub 2017 Mar 3.

Supplemental Content

Loading ...
Support Center